Our verdict is Pathogenic. Variant got 14 ACMG points: 14P and 0B. PVS1PS1_ModeratePM2PP5_Moderate
The NM_000249.4(MLH1):c.1A>T(p.Met1?) variant causes a initiator codon change involving the alteration of a non-conserved nucleotide. The variant was absent in control chromosomes in GnomAD project. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Pathogenic (★).
MLH1 (HGNC:7127): (mutL homolog 1) The protein encoded by this gene can heterodimerize with mismatch repair endonuclease PMS2 to form MutL alpha, part of the DNA mismatch repair system. When MutL alpha is bound by MutS beta and some accessory proteins, the PMS2 subunit of MutL alpha introduces a single-strand break near DNA mismatches, providing an entry point for exonuclease degradation. The encoded protein is also involved in DNA damage signaling and can heterodimerize with DNA mismatch repair protein MLH3 to form MutL gamma, which is involved in meiosis. This gene was identified as a locus frequently mutated in hereditary nonpolyposis colon cancer (HNPCC). [provided by RefSeq, Aug 2017]
Verdict is Pathogenic. Variant got 14 ACMG points.
PVS1
Start lost variant, next in-frame start position is after 34 pathogenic variants. Next in-frame start position is after 35 codons. Genomic position: 36993650. Lost 0.045 part of the original CDS.
PS1
Another start lost variant in NM_000249.4 (MLH1) was described as [Pathogenic] in Lovd
PM2
Very rare variant in population databases, with high coverage;
PP5
Variant 3-36993548-A-T is Pathogenic according to our data. Variant chr3-36993548-A-T is described in ClinVar as [Pathogenic]. Clinvar id is 1255698.Status of the report is criteria_provided_single_submitter, 1 stars.
Review Status: criteria provided, single submitter
Collection Method: clinical testing
The p.M1? pathogenic mutation (also known as c.1A>T), located in coding exon 1 of the MLH1 gene, results from an A to T substitution at nucleotide position 1. This alters the methionine residue at the initiation codon (ATG). This variant has been reported in an individual with colorectal cancer who underwent cancer multi-gene testing (Akcay IM et al. Int J Cancer, 2021 01;148:285-295). Another alteration affecting the initiation codon, p.M1? (c.3G>A), has been detected in multiple Lynch syndrome families meeting Amsterdam criteria (Guillem JG et al. Ann Surg. 2007 Apr;245(4):560-5; Ambry internal data). Sequence variations that modify the initiation codon are expected to result in either loss of translation initiation, N-terminal truncation, or cause a shift in the mRNA reading frame. Based on the supporting evidence, this alteration is interpreted as a disease-causing mutation. -